*2.4. Placental sFlt-1, TNF-α, and IL-6 Expression Were Inhibited by PDMSCs-CM in PE Mice*

In order to determine if PDMSCs-CM treatment was effective also at the placental level, we evaluated placental expression of sFlt-1, TNF-α, and IL-6, key hallmarks of preeclampsia, in CM and control mice. We found a significant reduction of mRNA expression for the three molecular targets investigated, namely sFlt-1 (5.5-fold decrease, *p* = 0.04), TNF-α (6.2-fold decrease, *p* = 0.03), and IL-6 (5-fold decrease, *p* = 0.03) in CM mice compared to controls (Figure 2A). Decreased sFlt-1 (*p* = 0.013, 1.29-fold decrease) and IL-6 (*p* = 0.034, 1.14-fold decrease) expression in the placentae of CM mice, compared to controls, was confirmed also at the protein level (Figure 2B). No significant differences in TNF-α protein level were found in CM compared to control placentae (Figure 2B).

**Figure 2.** Effects of PDMSCs-CM treatment on placental sFlt-1, TNF-α, and IL-6 expression. Gene (**A**) and protein (**B**) sFlt-1, TNF-α, and IL-6 expression in placentae from LPS-induced PE mouse model injected with PDMSCs-CM or plain media. Statistical significance (\*) has been considered as *p* < 0.05.
